A large Swedish longitudinal study has produced a finding that deserves serious attention from clinicians and policymakers alike: poor cognitive performance in one’s sixties is a meaningful predictor of stroke in the years that follow.
Published in the Journal of the American Heart Association, the research followed nearly 5,000 adults aged 60 and above — none of whom had any prior history of dementia, stroke, or transient ischaemic attack — over an average follow-up period of 12.3 years. Drawing on data collected between 2001 and 2023 through the Good Aging in Skåne project and the Swedish National Patient Register, the study tracked first-time stroke events against baseline cognitive assessments covering overall thinking ability, memory, processing speed, verbal fluency, and executive function. By the end of the follow-up period, more than 10 per cent of participants — 572 individuals in total — had experienced a stroke.
The central finding is both striking and clinically actionable. Among adults in their sixties specifically, those who scored in the lowest cognitive performance band faced an 86 per cent higher risk of stroke when measured against those in the highest band for overall thinking ability. Lower memory scores corresponded to a 68 per cent higher stroke risk, and reduced information-processing speed was associated with a 66 per cent elevated risk. These are not marginal statistical associations; they represent substantial differentials that, if replicable, carry real implications for how we approach preventive medicine in midlife.
Crucially, the same pattern did not hold for participants aged 70 to 79 or those aged 80 and above, once researchers adjusted for other health and lifestyle variables. Lead author Alice Askemyr, a geriatrics researcher at Lund University and Skåne University Hospital in Malmö, offered a persuasive explanation for this age-specific divergence. The older cohorts are considerably more heterogeneous in their medical profiles — burdened by multiple concurrent conditions and polypharmacy — making it far harder to isolate cognitive performance as a discrete signal. In one’s sixties, by contrast, the medical landscape is comparatively uncluttered, and a cognitive deficit stands out more clearly as an independent marker of underlying pathology.
Askemyr also raised the possibility that lower cognitive scores in younger participants may reflect so-called silent brain injuries — subclinical lesions that affect both cognition and future stroke risk without producing overt neurological symptoms. Such injuries are thought to affect roughly 70 per cent of adults over 70, but their effects may be detectable earlier precisely because competing confounders are less prevalent in the sixth decade of life. This hypothesis is scientifically plausible and lends the findings a mechanistic coherence that pure correlation studies often lack.
Elisabeth Breese Marsh, professor of neurology and director of the Bayview Stroke Center at Johns Hopkins University School of Medicine, who was not involved in the research, reinforced this reading while extending its scope. She argued that the evidence supports aggressive management of vascular risk factors well before most patients or their doctors begin to consider it — pointing to people in their forties and fifties as the appropriate target for preventive intervention. Her observation that the study also opens the door to cognitive testing as a screening tool for elevated stroke risk adds a practical dimension that health systems would do well to consider.
The study’s limitations are acknowledged straightforwardly. It is observational in design, establishing association rather than causation, and its findings may not generalise beyond Sweden given differences in healthcare provision, socioeconomic conditions, and lifestyle habits across countries. These are standard caveats, not disqualifying ones. What the research does establish — with a sample size of nearly 5,000 and a follow-up period of over a decade — is that measurable cognitive decline in midlife is not merely a symptom to be managed but potentially a warning signal to be acted upon. The case for earlier, more systematic attention to brain health, grounded in empirical evidence rather than therapeutic optimism, has grown considerably stronger.